Number of employees: 7
Overview & History:
GLS Capital is a US-based litigation finance firm with more than $345 million under management. Founded by litigation finance industry veterans who have originated, evaluated, and managed hundreds of millions of dollars in litigation finance investments, GLS invests in a wide variety of complex situations dependent upon legal or regulatory risk. GLS focuses on three areas of investment: complex commercial litigation and arbitration, patent infringement litigation, and life sciences litigation. Working with law firms and litigants worldwide, with a focus in the United States, GLS invests between $1-$50 million per investment.
GLS prides itself on its decision-making speed and the pace of its investment process. Its deep industry experience also affords unique insights into the evaluation and management of litigation finance investments. Armed with a broad investment mandate, all investment decisions are made internally by the GLS investment committee, which provides certainty and transparency for counterparties throughout the investment lifecycle.
Complex Commercial Litigation and Arbitration Finance:
GLS devotes a considerable portion of its portfolio to investments relating to complex commercial litigation and arbitration. These generally are business-to-business disputes, with the underlying legal claims involving breach of contract, trade secret misappropriation, competition, tortious interference, insolvency, asset recovery, and investment treaty arbitration, among others. GLS invests with respect to both single cases and portfolios of cases involving complex commercial litigation and arbitration, both in the US and worldwide.
David Spiegel and Jeffery Lula lead commercial litigation and arbitration investments for GLS.
Patent Infringement Litigation Finance:
GLS also has a particular specialty relating to technology-related patent infringement litigation. The firm’s principals have invested in intellectual property-related disputes longer than almost any other litigation finance firm. GLS boasts a deep bench of investment professionals who hold considerable hard science and patent litigation experience, all of whom were formerly patent litigators at elite law firms and Fortune 500 companies.
Providing capital to both inventors and law firms, GLS participates in patent litigationrelated investments across a broad spectrum of cutting-edge technologies, including semiconductors, consumer electronics, medical devices, telecom, and industrial machinery, among others. The investments primarily focus on litigation finance for single cases or a portfolio of cases, but the firm also opportunistically participates in financing the purchase and monetization of large patent portfolios. GLS’s patent litigation investments have a US focus, but GLS has also participated in investments involving international enforcement.
Adam Gill and Joel Merkin lead patent infringement litigation investments for GLS.
Life Sciences Litigation Finance:
GLS has expertise in a broad range of litigation-related investments that arise in the life sciences industry. The GLS team has decades of experience and a deep understanding of the complex supply chain, regulatory, and commercial environments for pharmaceutical, medical device and health care companies.
GLS brings together significant technical, industry, and legal experience to underwrite virtually any commercial litigation claim across the life sciences landscape. This industry know-how allows GLS to quickly and accurately underwrite and invest in the complex litigation that develops in the life sciences industry – namely claims regarding pharmaceutical (i.e. Hatch-Waxman) litigation, breach of contract, trade secret misappropriation, and competition, among others.
Jamie Lynch and Dr. Lauren Rabinovic lead GLS’s investments in the life sciences industry.